Loading clinical trials...

The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine | Clinical Trials | Clareo Health

RECRUITINGPHASE4

The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine

Polyene Phosphatidylcholine Injection for the Treatment of Perioperative Liver Injury With Laparoscopic Hemihepatectomy in Hepatocellular Carcinoma: a Multicenter Randomized Controlled Study

NCT07150624•Anhui Provincial Hospital

View on ClinicalTrials.gov

Summary

A multicenter, open-label, randomized, controlled study. It is proposed to evaluate the treatment plan of receiving 930mg polyene phosphatidylcholine injection one day before the operation, twice a day, and 930mg polyene phosphatidylcholine injection twice a day,combined with 100mg of magnesium isoglycyrrhizinate injection once a day,from the 1st to the 5th day after the operation. Compared with the monotherapy regimen of no liver protection treatment before the operation and receiving magnesium isoglycyrrhizinate injection 100mg once a day from the 1st to the 5th day after the operation.The efficacy and safety of treating postoperative liver function injury in patients undergoing laparoscopic hemihepatectomy for hepatocellular carcinoma were compared.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Diagnosed as HCC through imaging and laboratory tests, and capable of undergoing laparoscopic anatomical resection
•2. Those who plan to undergo right or left hemi-liver resection
•3. During the operation, the Pringle method was used to block the first hepatic portal. Each block lasted for no more than 15 minutes, and the blocking procedure was performed 2 to 4 times.
•4. Age: 18 - 70 years old. Gender: Open to both male and female. Body Mass Index (BMI): 18.5 - 28 kg/m2
•5. Child-Pugh grade A or B, with a score of ≤ 7; ASA grades I to III
•6. Preoperative ICG R15 was less than 10%, and the residual liver volume was more than 40% of the standard liver volume
•7. A single HCC (hepatocellular carcinoma), with a tumor diameter less than 10 cm, without distant metastasis or invasion of the portal vein system
•8. Preoperative ALT was less than 2 times the upper limit of normal
•9. Before being enrolled in the study, the patient had no history of any other treatments, such as portal vein embolization, TACE or systemic anti-tumor drug therapy.
•10. No liver-damaging treatment drugs were used within two weeks prior to enrollment.

Exclusion Criteria

•1. Reserve liver vascular damage, including: reconstruction after severance, ligation, embolization, thrombosis, etc
•2. Combined with abnormal coagulation function (prothrombin time prolonged by more than 3 seconds)
•3. Combining obstructive jaundice, severe heart disease, severe kidney disease and other serious illnesses
•4. During the operation, microwave treatment or a combination of microwave treatment was adopted
•5. More than 4 times of blocking at the first hepatic hilum, or a single blocking duration longer than 15 minutes
•6. Non-anatomic liver resection, where the remaining liver contains large areas of ischemic/edematous regions
•7. More than 1000ml of blood transfusion during the operation
•8. During the operation, an extra-hepatic disease was discovered. Other organs except the gallbladder needed to be removed simultaneously
•9. During the operation, other intrahepatic lesions were discovered, which required combination with other surgeries, such as ablation or choledochojejunostomy
•10. Diseases that have previously received systemic treatment with glucocorticoids, such as chronic kidney disease, inflammatory diseases, or other immune system-related disorders
+5 more criteria

Locations (1)

Anhui Provincial Hospital

Hefei, Anhui, China

Key Dates

Start Date

August 30, 2025

Primary Completion Date

February 28, 2026

Completion Date

March 31, 2026

Last Updated

September 2, 2025

Enrollment

ESTIMATED participants

Conditions

Hepatocellular Carcinoma (HCC)Liver Diseases

Interventions

Experimental Group

DRUG

control group

DRUG

Contacts

Lianxin Liu

CONTACT

0551-96512 liulx@ustc.edu.cn

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT07291076

Hepatocellular Carcinoma (HCC)

View study

RECRUITING

NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

NCT07365930

Hepatocellular Carcinoma (HCC)

View study

RECRUITING

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 2, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial

A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma

Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab